52 results about "MMP2" patented technology

The invention discloses a method of identifying a gene associated with stage III primary cancer or lymph node metastasis. The genes so identified include CAV1, CST3, LIMK1, MMP2, MMP15, VEGF, ETV4, MMP9, PIK3C2B, and SERPIN1. Also disclosed are methods for diagnosis, prognosis, and treatment of cancer. The invention further discloses compositions for preventing and treating diseases.

Disclosed are compositions useful for treating Alzheimer's disease, atherosclerosis, arteriosclerosis, osteoarthritis and other degenerative joint diseases, Huntington's chorea, Parkinson's disease, optic atrophy, retinitis pigmentosa, macular degeneration, muscular dystrophy, aging-associated degenerative processes, asthma, dermatitis, laminitis, pemphigoid, pemphigus, reactive airway disease (e.g., COPD, IAD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), multiple sclerosis, rheumatoid arthritis, periodontal disease, systemic lupus erythematosus, sarcoidosis, psoriasis, type I diabetes, ischemia-reperfusion injury, chronic inflammatory diseases, geriatric wasting, cancer cachexia, cachexia associated with chronic inflammation, sick feeling syndrome, and other inflammatory and / or degenerative diseases, disorders, conditions, and processes in humans and other animals. In one embodiment, the compositions include at least 4 of the following: a MMP1 inhibitor, a MMP2 inhibitor, a MMP3 inhibitor, a MMP7 inhibitor, a MMP9 inhibitor, an ADAMTS-4 inhibitor, a MMP13 inhibitor, and a MMP14 inhibitor. In another embodiment, the compositions include a curcuminoid, a polymethoxylated flavone, a catechin, and a boswellic acid.

The invention relates to a gene detection kit for prognosing gastric cancer metastasis. The kit comprises a DNA library building kit, wherein the DNA library building kit comprises a high-risk gene probe and a low-risk gene probe; the high-risk gene probe comprises CDH1, CDH2, SNAIL, SLUG, MUC4, MUC6, PRSS3, USP6, MLH1, MSH2, MSH6, PMS2, TGFBR2, MMP2, MMP9, BRCA1, BRCA2, PALB2, ATM, ATR, MUTYH, EMSY, ERCC4, RAD51, PARP1 and XRCC1; the low-risk gene probe comprises ATRX, BRIP1, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FANCO, FANCP, MDM2, MDM4, MLH1, NPM1, PP2R1A, PRKDC, RAD50, STAG2, XRCC5 and CRCC6. The invention further discloses a use method of the kit. The use method comprises the following steps: extracting cfDNA in a blood sample; building a library for the cfDNA through the DNA library building kit, and then sequencing the DNA to obtain a gene overall length sequence; carrying out gene mutation analysis on the gene overall length sequence.

Angiogenesis, tumor growth, and metalloproteinase 2 (MMP2) interaction with integrin-αvβ3 are inhibited by an inhibitor compound of formula (I): wherein G1 and G2 are each independently NH—C(O)—O—R1, —NH—C(O)—O—(CH2)v—(C6H4)—X3, —NH—C(O)—NH—(CH2)v—(C6H4)—X3, —O—C(O)—NH—(CH2)v—(C6H4)—X3, —O—C(O)—O—(CH2)v—(C6H4)—X3, or NH—C(O)—CH2—(C6H4)—X3; Y1 and Y2 are each independently OH, C1–C4 alkyl, C1–C4 hydroxyalkyl, C1–C4 alkoxy, phenyl, benzyl, or NH2; R1 is C1–C4 alkyl; X1 and X2 are each independently halo or C1–C4 alkoxy; X3 is halo, nitro, C1–C4 alkyl, C1–C4 alkoxy, or C1–C4 perfluoroalkyl; Z is —C≡C—, —C6H4—, cis-CH═CH—, trans CH═CH—, cis-CH2—CH═CH—CH2—, trans —CH2—CH═CH—CH2—, 1,4-naphthyl, cis-1,3-cyclohexyl, trans-1, 3-cyclohexyl, cis-1,4-cyclohexyl, or trans-1,4-cyclohexyl; A is H or a covalent bond; m and n are each independently an integer having a value of 0 or 1; t is an integer having a value of 0 or 1; and p, r, and v are each independently an integer having a value of 1 or 2; with provisos that when A is H, t is O; when A is a covalent bond, t is 1; when m is 0, Y1 is C1–C4 hydroxyalkyl; and when n is 0, Y2 is C1 C4 hydroxyalkyl.

The invention discloses an osteosarcoma circulating tumor cell identification kit. The kit comprises capture probes for marker gene mRNAs and a signal amplification system. The marker genes comprise at least two epithelial cell marker genes selected from EpCAM, CDH1, KRT8, KRT16, KRT17, KRT18, KRT19 and KRT20 and at least two osteosarcoma metastasis-related interstitial cell marker genes selected from MMP2, MMP9, VIM, CDH2, FN1, HIF-1a, SERPINE1, SURVIVIN, TWIST1, AKT2 and SNAIL. The kit can completely detect osteosarcoma circulating tumor cells, evaluate their metastatic ability to avoid the possibility of the false negative result caused by different expression levels of CTCs in different types of cancers and further improve the accuracy of detection.

The invention discloses a kit for screening colorectal cancer hereditary susceptibility genes. The kit comprises colorectal cancer susceptibility gene specificity primers for amplifying a plurality of target regions in a to-be-detected sample, wherein the colorectal cancer susceptibility genes include at least one of rs10795668, MMP2, SMAD7, ADH2, ALDH2, CYP1A2, MMP-1, MTHFR, TP53, VEGF, COX-2, DNMT3B, hMLH1, LOC727677, MMP9, MTRR and TGF-beta 1. The kit can detect a plurality of regions of the colorectal cancer susceptibility genes at the same time, detecting efficiency is improved, detecting cost is reduced, and detecting accuracy and sensitivity are high.

The invention provides a computer system used in determination of recurrence risk of colorectal cancer. The computer system is provided with a computer including a processor and a storage. The storage is recorded with a computer program which is executed in the computer. The method comprises receiving expression quantity of a plurality of genes selected by a first gene group existed in a region of 18q21 to 18q23 on an eighteenth chromosome long chain in a live sample acquired from a colorectal cancer patient, receiving expression quantity of a plurality of genes selected by a second gene group existed in a region of 20q11 to 20q13 on an twentieth chromosome long chain in a live sample acquired from a colorectal cancer patient, and receiving expression quantity of a plurality of genes selected by a third gene group including ANGPTL2, AXL, C1R, C1S, CALHM2, CTSK, DCN, EMP3, GREM1, ITGAV, KLHL5, MMP2, RAB34, SELM, SRGAP2P1, and VIM in a live sample acquired from a colorectal cancer patient, and based on the received expression quantity, determining recurrence risk of colorectal cancer for the patient.

The invention provides methods and compositions for distinguishing ovarian cancer from a benign pelvic mass using two or more of the following biomarkers: IL-6, MMP9, tPA, IGFBP2, MMP7, Tenascin, NAP2, glycodelin, MCSF, MMP2, Inhibin A, uPAR, and EGFR. The methods are useful in distinguishing a benign pelvic mass from ovarian cancer in subjects, particularly in subjects identified as having increased CA125 levels.

The invention discloses an anti-atherosclerosis drug efficacy evaluation method based on inflammatory responses, wherein the method comprises the following steps: step 1, planting smooth muscle cells on the outer side of a Millicell@insert PE (Poly Ethylene) membrane, and turning after the cells are adhered to the wall for 8 hours; step 2, planting endothelial cells on the inner side of the membrane, and culturing for 6 days totally; step 3, inoculating mononuclear cells THP-1, adding oxLDL, IL-1 and texted drugs, and culturing for 24 hours; step 4, detecting any one of the items of detecting contents of MCP-1 and TNFa in the endothelial cells; detecting the content of CD36 on the surface of the mononuclear cells; detecting the contents of MDA and MMP2 in the smooth muscle cells, observing the change of a smooth muscle cytoskeleton; observing the expression of ICAM-1 of the endothelial cells.

The present invention provides methods of promoting arteriogenesis in a subject. Embodiments include methods comprising: administering an effective dose of tocotrienol to the subject; causing an increase in Tissue Inhibitor of Metalloproteinase Metallopeptidase Inhibitor 1 (TIMP1) in vessels of cerebrovascular collateral circulation in the subject; attenuating the activity of Matrix Metalloproteinase-2 (MMP2); thereby promoting arteriogenesis.

The invention belongs to the field of medicines, and relates to application of dihydrotanshinone I in preparation of anti-hepatic fibrosis medicines. Systematic researches on the inhibiting effect on the mRNA and protein level of fibrosis main markers (COL1A1, TGFB1, ACTA2 and MMP2) in a TGF beta 1 induced LX-2 cell, influence on contents of ALT and AST in the serum of a BDL rat, improvement on the pathological change of liver tissues of the BDL rat, influence on the content of hydroxyproline of liver tissues of the BDL rat, inhibition on the mRNA and protein level of fibrosis main markers of liver tissues of a rat, influence on the hepatic fibrosis degree of the rat prove that the dihydrotanshinone I has excellent anti-hepatic fibrosis activity, and is expected to be developed into novel anti-hepatic fibrosis medicines.

The invention provides 11SNPs markers of MMP3, MMP9, MMP2 and VDR genes or a combination of the markers. The 11SNPs markers or a combination are used for ONFH molecular early warning, clinical molecular diagnosis and typing, and drug therapy targets. The pairwise interaction of the 11SNPs is significantly related to the onset risk of ONFH, and the risk correlation is partially or completely different from the action of a single SNP on the onset risk of the ONFH, the synergistic effect of a plurality of SNPs on the onset risk of the ONFH is found more clearly according to the result of the geneinteraction, the ONFH is further verified to be a complex disease caused by combination of multiple micro-effect genes, the joint effect of the molecular genetics sites is elaborated, and the important value is achieved for ONFH early-stage molecular early warning and molecular prevention and control strategy establishment.

The present invention relates to fibulin-3 protein and a pharmaceutical composition comprising the fibulin-3 protein as an active ingredient for inhibiting the growth of cancer stem cells. More particularly, in cancer stem cells separated from H460 and A549 cells, which are non-small-cell lung cancer cells, using ALDH1 activity as a marker, fibulin-3 induces the reductions of wnt / β-catenin, MMP2 and 7, which display characteristics of cancer stem cells, thereby decreasing the activated growth and penetration of the cancer stem cells. In addition, the purified fibulin-3 protein inhibits the growth of the non-small-cell lung cancer cell line A549, the breast cancer cell line MDA-MB231, and the cancer stem cell line active ALDH1. Therefore, fibulin-3 can be valuably used as an active ingredient of the pharmaceutical composition for inhibiting the growth of cancer stem cells.

The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being:SPP1, andat least one gene from among A2M and VIM, andat least one gene from among IL8, CXCL10 and ENG, andoptionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.

The invention provides a cis-platinum carrier with MMP2 response, a preparation method of the cis-platinum carrier, a cis-platinum complex and a preparation method of the cis-platinum complex. The cis-platinum carrier provided by the invention has a structure as shown in a formula I, specific branched chain sulfhydrylation polyethylene glycol maleimide polypeptide is grafted on the side chain of polyamino acid, the cis-platinum carrier can be used as a shell of cis-platinum, has certain shielding capability and MMP-2 responsiveness, and is enriched at a tumor tissue part by enhancing an osmotic retention (EPR) effect; under other normal environments of a human body, the toxicity of cis-platinum can be prevented, and under the stimulation of active oxygen conditions of overexpression of a tumor prevention part, cis-platinum can be quickly responded, automatically removed and released, and plays a role in the tumor part. Therefore, sudden release and non-specific interaction in a blood circulation system after intravenous injection can be effectively avoided so that the toxicity is reduced.

This invention relates to a method for constructing recombinant adenovirus capable of secreting human PEX. The method comprises: constructing plasmid pSecTag A / PEX, constructing plasmid pGEX-4T-3 / PEX 215, amplifying PEX cDNA fragment of human MMP2 by PCR, constructing eukaryon expression plasmid pSecTag A / PEX, contructing pAdEasy-pShuttle-CMV-PEX (Ad-PEX) carrier, recombining Eschericia coli adenovirus, amplifying recombinant pAdEasy-pShuttle-CMV-PEX (Ad-PEX), and packaging to obtain intact recombinant adenovirus, which can be used in gene drugs for treating angiogenesis-related diseases, such as tumors.

Disclosed is a method for supporting a diagnosis of a risk of colorectal cancer recurrence, including the steps of: performing a first measurement to measure the levels of expression of a plurality of genes selected from a first gene group present in a region from 18q21 to 18q23 on the long arm of chromosome 18 in a biological sample collected from a patient with colorectal cancer, a second measurement to measure the levels of expression of a plurality of genes selected from a second gene group present in a region from 20q11 to 20q13 on the long arm of chromosome 20, and a third measurement to measure the levels of expression of a plurality of genes selected from a third gene group including ANGPTL2, AXL, C1R, C1S, CALHM2, CTSK, DCN, EMP3, GREM1, ITGAV, KLHL5, MMP2, RAB34, SELM, SRGAP2P1, and VIM; and determining the risk of colorectal cancer recurrence of the patient based on the levels of expression measured in the measurement step.

A transgenic non-human mammal has a genome that includes an early-immediate enhancer of human cytomegalovirus (CMV enhancer), a β-actin promoter and the entire gene region of human matrix metalloproteinase 2 (hMMP2) disposed downstream of the promoter. The hMMP2 is systemically expressed in the transgenic non-human mammal, which thus provides a suitable animal model for studying chronic obstructive pulmonary disease and related diseases and conditions.

The present invention particularly relates to a biosensor for detecting matrix metalloproteinases and an application of the biosensor. MMP2 and MMP7 are closely related to physiological activities ofvarious diseases, and a protease detection method commonly used at present has defects of high cost, insufficient detection sensitivity, etc. The present invention aims to provide the biosensor for detecting multiple matrix metalloproteases (MMPs) with high sensitivity, through a protease specific cracking reaction and an nickase assisted signal amplification (NESA) technology, specific and high-sensitivity simultaneous detection of the multiple matrix metalloproteases is realized, and the biosensor can also be applied to screening inhibitors of the matrix metalloproteases, etc.

The invention provides methods for identifying an individuals with a disease or disorder who is less likely to respond to immunotherapy alone, the method comprising determining the presence of a stromal gene signature in a sample from the individual, said signature comprising one or more of FAP, FN1, MMP2, PDGFRB, or THY, wherein an increase in the level of expression of the one or more genes in the stroma gene signature relative to a median level identifies an individual for treatment with an immunotherapy and with a suppressive stromal antagonist. In some aspects, the invention provides methods for treating an individual displaying the stromal gene signature. In other aspects, the invention provides kits for determining the presence of a stroma gene signature in a sample from an individual.

The invention discloses application of an HIF-1[alpha] inhibitor or an AR inhibitor or a combination of the HIF-1[alpha] inhibitor and the AR inhibitor in inhibiting inflammatory factor storm and preventing or treating viral pneumonia. According to the application, the HIF-1[alpha] inhibitor and the AR inhibitor are found to prevent transcription of inflammatory factor storm related genes (IL6, MMP2, MMP13, ADAMTS4, ELN, VCAN, COL3A1 and VEGFA) in a hypoxic environment in fibroblasts by effectively inhibiting mutual binding of HIF-1[alpha] and AR, so that the expression quantity of the relatedgenes is reduced, and activation of lung fibroblasts in the hypoxic environment is inhibited. Activation of the lung fibroblasts is inhibited, so that lung functions of acute respiratory distress syndrome (ARDS) patients with severe respiratory tract infection can be maintained, and clinical curative effects are improved; and moreover, the HIF-1[alpha] inhibitor and the AR inhibitor have the advantages of being low in cost, small in toxic and side effect and remarkable in curative effect, and a new strategy is provided for treatment of the viral pneumonia.

Biomarkers, biomarker panels and methods for diagnosing osteoarthritis (OA) and determining treatment are disclosed, using measurement of the expression level of certain polypeptides in a test sample from a subject, including MCP1, IL8, KC, MMP2, MMP3, Apolipoprotein A1, and Apolipoprotein E. Related methods for monitoring OA treatment efficacy, diagnostic reagents, and kits are also described.

The present invention relates to the use of a mixture of husband and wife grasses, and more particularly to the use of a mixture of husband and wife grass extracts for the preparation of a compositionfor inhibiting matrix metalloproteinase 2 (MMP2) gene expression and collagen breakdown. The husband and wife grass extract of the present invention is obtained by extracting the couple grass with water, an alcohol or an alcohol-water mixture as a solvent. The couple's grass extract reduces the decomposition of collagen in the skin by inhibiting the gene expression of MMP2 in the skin fibroblasts, thereby contributing to skin elasticity and firmness, reducing fine lines and wrinkles, and delaying skin aging.

The invention provides an application of a lignans compound in preparation of an anti-hepatic fibrosis medicine. In-vitro, in-vivo and molecular-level tests prove that the lignans compound has strongeffect of inhibiting proliferation of hepatic stellate cells and resisting the hepatic fibrosis, and also has lower IC50 value to matrix metalloproteinase-2 (MMP2), matrix metalloproteinase-9 (MMP9) and transforming growth factor-beta1 (TGF-beta1). The lignans compound can be combined with the substances mentioned hereinabove and can inhibit the bioactivities of the substances, so that the lignanscompound can be used as an anti-hepatic fibrosis medicine.

Inhibitors of matrix metalloproteinase 2 are used to treat or prevent a fibrotic disorder of the posterior capsule of the eye, for example posterior capsule opacification (PCO), or of a tissue or structure of the eye other than the lens or capsular bag.

The invention provides the application of a lignan compound in the preparation of anti-hepatic fibrosis medicine. After in vitro, in vivo, and molecular level experiments, the lignan compounds described in the present invention prove that they have strong anti-hepatic stellate cell proliferation effects, anti-hepatic fibrosis effects, and anti-matrix metalloproteinase-2 (MMP2), matrix metalloproteinase-9 (MMP9) and transforming growth factor-β1 (TGF-β1) all have low IC50 values, have good binding and inhibit their biological activity, so they can be used as anti-hepatic fibrosis drugs .

The invention discloses a kit for screening cancer brain metastases. The invention also discloses the use of the reagent for detecting the expression level of long-chain non-coding RNA lnc-MMP2-2 in the preparation of reagents for screening cancer brain metastasis. By detecting the expression level of lnc-MMP2-2, the kit of the present invention can determine the risk of brain metastases of lung cancer in the subject, can be used for auxiliary diagnosis of brain metastases of lung cancer, and provide effective basis for patients to take relevant treatment measures or decision-making , the clinical application prospect is good.